What are the Early Stages of Lupus? Incomplete lupus? Undifferentiated connective tissue disease? Pre-clinical autoimmune disease? https://t.co/kl1ePmQ5zf https://t.co/5MgIt4QyJV

5 yr prospective observational study of 246 pts w/ nonradiographic Axial Spa shows that 16% of nr-axSpA progressed to r-axSpA w/in 5 yrs. SI progression more likely w/ Male sex (HR 3.16), imaging sacroiliitis (HR 6.6), & good NSAID response (HR 4.6) https://t.co/kXXhYaNqRz https://t.co/OD0rowut9k

But MTX does not prevent CV events in cardiac rush pts (without rheum dz). Results of the CIRT trial. #RWCS24 https://t.co/45aLt6qf27

DMARDs, MTX & TNFi can lower CV risk in RA pts. #RWCS24 https://t.co/Un457RYL8R

Marketing analysis of systemic sclerosis prevalence estimates, from 7 major countries, ~150,000 SSc pts in 2022 (47% from US; 20% Japan; 10% UK). https://t.co/0zJFdq05Xd https://t.co/HWM3LNtHbS

Board question/clinical pearl alert: Hairy Kidney Sign is an important indicator of Erdheim-Chester. Dr. @anisha_dua #RWCS24 @RheumNow @RWCSmtg - abnormal histiocytes now classified as malignancy - bone pain common presenting complaint - can see aorta, pleura, pericardium… https://t.co/XO5GXSNJZk https://t.co/gBn8Hii7F0

Beautiful graphic from Lyu X describing CAR-T development/manufacturing. Dr. @susanshenoi #RWCS24 @RheumNow @RWCSmtg https://t.co/yujfZeBaW7

Hot off the press! Case report inspired by Dr. George Martin. Topical ruxolitinib efficacy in cutaneous DM. Dr. @susanshenoi #RWCS24 @RWCSmtg @RheumNow https://t.co/uyJdvgJ0ue

Ixekizumab Safety from 25 RCTs (17 PsO, 4 PsA, 4 axSpA) w/ 9225 pts (22371 PYs use). Long-term safety c/w earlier reports/PI. SAEs in 1204 (13%); 45 deaths); ISRs 5.9-11.6/100PYs; IBD ≤ 0.8/100PY; depression, CVA, Cancer : ≤ 1.6/100PY https://t.co/p7N6ZMVvqh https://t.co/22WYkevhaf

Gut microbiota in SpA. Interesting data from @RWCSmtg @JointMD regarding the gut microbiome, both shared and distinct, in SpA, non-infectious AAU and Crohn's. #RWCS24 @RheumNow https://t.co/tHGl01WJ1o

"It's hard not to be jealous of the dermatologists." @JointMD discussing the results of JNJ 77242113, po IL-23R, the Frontier 1 trial. #RWCS24 @RWCSmtg @RheumNow https://t.co/1zQ6bu5TM2

Current PsA treatment options. A review with @RWCSmtg @JointMD #RWCS24 @RheumNow https://t.co/9I0TfyILvQ